Recombinant Human TROP-2 His-tag Protein, CF

When Recombinant Human IGF-II R/IGF2R Protein (6418-GR) is immobilized at 1 µg/mL (100 µL/well), Recombinant Human TROP-2 His-tag Protein (Catalog # 11158-T2) binds with an ED50 of 20.0-200 ng/mL.

2 μg/lane of Recombinant Human TROP-2 His-tag Protein (Catalog # 11158-T2) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 32-57 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human TROP-2 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human IGF-II R/IGF2R (Catalog # 6418-GR) is immobilized at 1 µg/mL (100 µL/well), Recombinant Human TROP-2 His-tag (Catalog # 11158-T2) binds with an ED₅₀ of 20.0-200 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human TROP-2 protein
  His27-Thr274, with a C-terminal 6-His tag
• Accession #: P09758.3
• N-terminal Sequence: His27
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 29 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 32-57 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human TROP-2 His-tag Protein, CF

• Cell surface glycoprotein Trop-2
• EGP1
• EGP-1
• epithelial glycoprotein-1
• GA733-1
• GA733-1GP50
• gastrointestinal tumor-associated antigen GA7331
• gp50
• M1S1cell surface glycoprotein TROP2
• Membrane component chromosome 1 surface marker 1
• membrane component, chromosome 1, surface marker 1
• Pancreatic carcinoma marker protein GA733-1
• pancreatic carcinoma marker protein GA7331,40kD glycoprotein, identified by monoclonal GA733
• T16
• TACSTD2
• TROP2
• TROP-2
• TROP2GA7331
• tumor-associated calcium signal transducer 2

Background

Human TROP-2, also called tumor associated calcium signal transducer 2 (TACSTD2), GA733-1, gp50 and T16, is a type I cell surface glycoprotein that is highly expressed on human carcinomas. It was originally identified as an antigen present on human gastrointestinal tumors and is the second of two members of this family. The other family member is GA733-2, also called EpCAM, TROP-1, 17-1A, gp40 and KSA. The TROP-2 gene is unique in that it contains no introns. A study of these two genes suggested that TROP-2 was the result of a retroposition of the EpCAM gene. TROP-2 and EpCAM share approximately 49% amino acid identity and approximately 67% similarity. Human and mouse TROP-2 share 87% similarity. The human TROP-2 protein consists of a putative 26 amino acid (aa) signal sequence, a 248 aa extracellular domain, a 23 aa transmembrane region and a 26 aa cytoplasmic domain. TROP-2 is transducing an intracellular calcium signal and may play a role in tumor growth. TROP-2 is associated with EGF mutation and resistance to drug treatment in many tumors. It has been discovered to bind to IGF IIR and promote IGF2-IGF1R-Akt (6). TROP-2 has emerged as a novel cancer target and a target for antibody-drug conjugates (7). TROP-2 interacts with ADAM-10 and binds E-Cadherin stimulating ADAM-10 mediated cleavage (8).

1. Linnenbach, A.J. et al. (1989) Proc. Natl. Acad. Sci. USA 86:27.
2. Linnenbach, A.J. et al. (1993) Mol. Cell. Biol. 13:1507.
3. Fornaro, M. et al. (1995) Int. J. Cancer 62:610.
4. Ripani, E. et al. (1998) Int. J. Cancer 76:671.
5. El Sewedy, T. et al. (1998) Int. J. Cancer 75:324.
6. Sun, X. et al. (2021) J. Cancer 12:5310.
7. Goldenberg, D. M. et al. (2018) Oncotarget. 9:28989.
8. Guerra, E. et al. (2021) Neoplasia. 23:898.

Bioinformatics

• Uniprot:
  • P09758.3()